Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD .
It may also improve local symptoms .
Until further evidence on the relative effectiveness of different lipid-lowering agents is available , use of a statin in people with PAD and a blood cholesterol level > /=3.5 mmol/litre is most indicated
BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease .
It may also reduce cardiovascular events and /or local disease progression in people with lower limb peripheral arterial disease ( PAD ) .
OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality , cardiovascular events and local disease progression in patients with PAD of the lower limb .
The treatment of intermittent claudication with betapyridyl carbinol over two years.
Abstract Forty-six patients with clinical ly significant peripheral atherosclerosis were r and omly allocated into two groups ; one receiving tablets of betapyridyl carbinol , up to 1800 mg daily , the other receiving a placebo . Patients were assessed clinical ly and their performance on a treadmill measured over intervals for two years . Plasma lipids were also measured . There was a slightly significant improvement in clinical findings after two years in those receiving drug treatment but no difference in symptoms . Treadmill performance appeared to improve equally in both placebo and drug treated groups . The plasma cholesterol fell significantly in the treated group compared the controls but the plasma triglycerides were not altered . Drop-outs from the trial did not differ significantly between the two groups . Two cases of hepatocellular dysfunction were attributable to betapyridyl carbinol
Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD .
It may also improve local symptoms .
Until further evidence on the relative effectiveness of different lipid-lowering agents is available , use of a statin in people with PAD and a blood cholesterol level > /=3.5 mmol/litre is most indicated
BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease .
It may also reduce cardiovascular events and /or local disease progression in people with lower limb peripheral arterial disease ( PAD ) .
OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality , cardiovascular events and local disease progression in patients with PAD of the lower limb .